GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcellx Inc (NAS:ACLX) » Definitions » Earnings Yield (Joel Greenblatt) %

Arcellx (Arcellx) Earnings Yield (Joel Greenblatt) % : -2.88% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Arcellx Earnings Yield (Joel Greenblatt) %?

Arcellx's Enterprise Value for the quarter that ended in Dec. 2023 was $2,297.2 Mil. Arcellx's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-66.2 Mil. Arcellx's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -2.88%.

The historical rank and industry rank for Arcellx's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

ACLX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -20.24   Med: -9.82   Max: -2.26
Current: -2.97

During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Arcellx was -2.26%. The lowest was -20.24%. And the median was -9.82%.

ACLX's Earnings Yield (Joel Greenblatt) % is ranked better than
72.57% of 1400 companies
in the Biotechnology industry
Industry Median: -14.76 vs ACLX: -2.97

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Arcellx's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Arcellx Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Arcellx's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcellx Earnings Yield (Joel Greenblatt) % Chart

Arcellx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - - -15.58 -2.88

Arcellx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.58 -18.18 -16.10 -8.87 -2.88

Competitive Comparison of Arcellx's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Arcellx's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcellx's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcellx's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Arcellx's Earnings Yield (Joel Greenblatt) % falls into.



Arcellx Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Arcellxs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-66.185/2297.15355
=-2.88 %

Arcellx's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.2 Mil.



Arcellx  (NAS:ACLX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Arcellx Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Arcellx's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcellx (Arcellx) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcellx Inc (NAS:ACLX) » Definitions » Earnings Yield (Joel Greenblatt) %
Traded in Other Exchanges
N/A
Address
25 West Watkins Mill Road, Suite A, Gaithersburg, MD, USA, 20878
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
Executives
Michelle Gilson officer: Chief Financial Officer 25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG MD 20878
Christopher Heery officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Rami Elghandour director, officer: See Remarks 15 BARCELONA CIR, REDWOOD CITY CA 94065
Jill Carroll director C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Sr One Capital Management, Llc 10 percent owner 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Sr One Co-invest Ii Manager, Llc 10 percent owner 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093

Arcellx (Arcellx) Headlines